BiPAP Use in Acute Heart Failure

Introduction to Non-Invasive Ventilation

The European Society of Cardiology provides a Class IIa recommendation (Level B evidence) for non-invasive positive pressure ventilation in acute heart failure patients with respiratory distress, specifically when respiratory rate >25 breaths/min and SpO2 <90% 1, 2, 3

The European Society of Cardiology recommends starting non-invasive ventilation if respiratory rate >25 breaths/min and SpO2 <90%, and the patient is not hypotensive 1, 2, 3
Non-invasive positive pressure ventilation can reduce blood pressure and should be used with caution in hypotensive patients, with regular blood pressure monitoring 1, 2, 3

The American Heart Association and European Society of Cardiology suggest that BiPAP may be associated with higher myocardial infarction rates compared to CPAP, though this remains controversial 4, 5, 6, 7
BiPAP is particularly useful in heart failure patients with hypercapnia, especially those with coexisting COPD or signs of respiratory muscle fatigue, as the inspiratory pressure support improves minute ventilation 1, 2, 3

The European Society of Cardiology recommends monitoring SpO2, respiratory rate, blood pressure, and mental status, and obtaining arterial or venous blood gas (check pH, PaCO2, lactate) 1, 2
Prefer CPAP initially for most acute heart failure patients, but consider BiPAP specifically if hypercapnia is present, acidosis, history of COPD, or signs of respiratory muscle fatigue 1, 2, 3
Monitor blood pressure continuously and discontinue non-invasive ventilation if hypotension develops, and monitor cardiac biomarkers given MI concerns 1, 2, 3, 4, 5, 8

Never use non-invasive ventilation in hypotensive patients, as positive pressure can further compromise hemodynamics, and avoid hyperoxia as it causes vasoconstriction and reduces cardiac output 1, 2, 3, 8
Be vigilant for myocardial infarction when using BiPAP, though more recent evidence suggests this risk may have been overstated in earlier studies 4, 8

Non-invasive ventilation should always be combined with appropriate pharmacological management including nitrates, diuretics, and other evidence-based treatments for acute heart failure 8

BiPAP causes hypotension primarily by increasing intrathoracic pressure, which reduces venous return to the heart, thereby decreasing cardiac output—this effect is particularly pronounced in hypovolemic patients or those with pre-existing low cardiac output states 9

In hypovolemic or relatively hypovolemic patients, positive pressure ventilation can precipitate severe hypotension or even cardiovascular collapse 9
The European trauma guidelines explicitly warn that fluid administration is usually required when introducing positive intrathoracic pressure in hypovolemic patients 9
Ensure adequate intravascular volume before applying positive pressure in trauma, sepsis, or dehydrated patients 9
Never apply BiPAP to hypotensive patients without first correcting volume status—the positive intrathoracic pressure will exacerbate shock 9
Avoid excessive ventilation rates, as hyperventilation combined with positive pressure creates additive negative effects on venous return 9

The American College of Emergency Physicians suggests starting with FiO₂: 100% initially, then titrate down if SpO₂ >95% 10
BiPAP may be associated with higher myocardial infarction rates compared to CPAP in pure cardiogenic pulmonary edema, though this remains controversial 10

The American Heart Association recommends preparing for intubation if depressed consciousness or inability to protect airway occurs 10
Cardiac biomarkers should be monitored given MI concerns with BiPAP 10

The American College of Emergency Physicians advises against using BiPAP when patient is hypotensive, as positive pressure reduces preload further 10
Low baseline PaCO₂ predicts BiPAP failure in heart failure 10
Active myocardial infarction is suspected, with earlier studies showing 71% MI rate with BiPAP vs 31% with CPAP 10